HER2/Neu Positive Terminated Phase 1 Trials for Lapatinib (DB01259)

IndicationStatusPhase
DBCOND0037939 (HER2/Neu Positive)Terminated1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01281163Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast CancerTreatment